Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 1.00 |
| ▸ | NPC1 | O15118 | 10/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 1.00 |
| ▸ | PKM | P14618 | 6/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9911667 | 0.84 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2PKMTP53 | |
| SCHEMBL14029255 | 0.77 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2PKMTP53 | |
| SCHEMBL15022003 | 0.77 | RAB9A (0.78) | RAB9ANPC1SMN1; SMN2PKMTP53 | |
| SCHEMBL19899495 | 0.75 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2PKMTP53 | |
| SCHEMBL21417048 | 0.74 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2PKMTP53 | |
| SCHEMBL3957488 | 0.72 | NPC1 (0.67) | RAB9ANPC1SMN1; SMN2PKMTP53 | |
| SCHEMBL5851841 | 0.72 | NPC1 (0.75) | RAB9ANPC1SMN1; SMN2PKMTP53 | |
| SCHEMBL15688417 | 0.72 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2PKMTP53 | |
| SCHEMBL27886383 | 0.72 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2PKMTP53 | |
| SCHEMBL10639656 | 0.72 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2PKMTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-16 | — | — | US | disclosed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | disclosed |
| US-20130289022-A1 | TETRAMERIC ALPHA-SYNUCLEIN AND USE THEREOF | BRANDEIS UNIVERSITY (US) | 2013-10-31 | — | — | US | disclosed |
| US-8518980-B2 | Treatment of Duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-27 | — | — | US | disclosed |
| US-8501713-B2 | Drug combinations for the treatment of duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-06 | — | — | US | disclosed |
| US-8440705-B2 | 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440705-B2 | 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2433634-A2 | Compounds, compositions and methods of inhibiting a-synuclein toxicity | The Whitehead Institute for Biomedical Research (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | SNCA, PARK7, HTT | RAB9A 912/4885NPC1 2064/4885SMN1; SMN2 41/4885 |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | RAB9A 3748/4885NPC1 2477/4885SMN1; SMN2 4/4885 |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | PYGM, CPT1B, GYS1 | RAB9A 3748/4885NPC1 2477/4885SMN1; SMN2 4/4885 |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | RAB9A 4325/4885NPC1 3637/4885SMN1; SMN2 9/4885 |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | RAB9A 4325/4885NPC1 3637/4885SMN1; SMN2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.